39845056|t|Probiotic Bacillus pumilus LV149 enhances gut repair, modulates microbiota, and alters transcriptome in DSS-induced colitis mice.
39845056|a|Purpose: Gut microbiota dysbiosis significantly impacts ulcerative colitis (UC) progression and exacerbation. Probiotics show promise in UC management. This study evaluated the effects of different doses of Bacillus pumilus LV149, an aquatic-derived probiotic, on gut injury repair in male C57BL/6 mice with dextran sulfate sodium (DSS)-induced ulcerative colitis (UC) and investigated the underlying mechanisms. Methods: UC was induced by allowing mice free access to a 3% DSS solution for 7 days, with concurrent daily oral gavage of either a low (LV149-L, 1 x 108 CFU/day/mouse) or high (LV149-H, 1 x 109 CFU/day/mouse) dose of LV149. The effects were assessed through physiological parameters, intestinal barrier integrity, inflammation, gut microbiota composition, and transcriptomic changes. Results: LV149 significantly improved pathological symptoms, including weight loss and disease activity index (DAI), and reduced colon shortening in a dose-dependent manner and inflammatory damage. The intervention also restored gut barrier function by upregulating mucins, goblet cell counts, and tight junction proteins (ZO-1, occludin, and claudin-1) in colonic tissue, along with reducing serum lipopolysaccharide (LPS) levels. Notably, only the LV149-H significantly decreased the expression of pro-inflammatory cytokines TNF-alpha, IL-1beta, and IL-6, while both doses increased the expression of the anti-inflammatory cytokine IL-10 in a dose-dependent in colonic tissue. LV149 further modulated the gut microbiota, increasing beneficial bacteria and reducing pathogenic populations. Transcriptomic analysis indicated that LV149-L may exert gut repair effects via the IL-17 signaling pathway, whereas LV149-H appears to act through the JAK-STAT signaling pathway. Conclusion: This study demonstrated that LV149, particularly at a higher dose, effectively mitigated DSS-induced colonic injury by modulating gut microbiota, enhancing gut barrier integrity, and reducing inflammation. The dose-dependent effects underscored LV149-H's potential as a therapeutic agent for UC due to its stronger anti-inflammatory properties and gut-protective effects.
39845056	104	107	DSS	Chemical	MESH:D016264
39845056	116	123	colitis	Disease	MESH:D003092
39845056	124	128	mice	Species	10090
39845056	186	204	ulcerative colitis	Disease	MESH:D003093
39845056	206	208	UC	Disease	MESH:D003093
39845056	267	269	UC	Disease	MESH:D003093
39845056	394	404	gut injury	Disease	MESH:C536735
39845056	420	427	C57BL/6	CellLine	CVCL:C0MU
39845056	428	432	mice	Species	10090
39845056	438	460	dextran sulfate sodium	Chemical	MESH:D016264
39845056	462	465	DSS	Chemical	MESH:D016264
39845056	475	493	ulcerative colitis	Disease	MESH:D003093
39845056	495	497	UC	Disease	MESH:D003093
39845056	552	554	UC	Disease	MESH:D003093
39845056	579	583	mice	Species	10090
39845056	604	607	DSS	Chemical	MESH:D016264
39845056	680	687	LV149-L	CellLine	CVCL:0C20
39845056	705	710	mouse	Species	10090
39845056	721	728	LV149-H	CellLine	CVCL:0C20
39845056	746	751	mouse	Species	10090
39845056	761	766	LV149	Chemical	-
39845056	858	870	inflammation	Disease	MESH:D007249
39845056	937	942	LV149	Chemical	-
39845056	999	1010	weight loss	Disease	MESH:D015431
39845056	1105	1124	inflammatory damage	Disease	MESH:D018746
39845056	1251	1255	ZO-1	Gene	21872
39845056	1257	1265	occludin	Gene	18260
39845056	1271	1280	claudin-1	Gene	12737
39845056	1327	1345	lipopolysaccharide	Chemical	MESH:D008070
39845056	1347	1350	LPS	Chemical	MESH:D008070
39845056	1378	1385	LV149-H	Chemical	-
39845056	1432	1444	inflammatory	Disease	MESH:D007249
39845056	1455	1464	TNF-alpha	Gene	21926
39845056	1466	1474	IL-1beta	Gene	16176
39845056	1480	1484	IL-6	Gene	16193
39845056	1540	1552	inflammatory	Disease	MESH:D007249
39845056	1562	1567	IL-10	Gene	16153
39845056	1803	1808	IL-17	Gene	16171
39845056	1940	1945	LV149	Chemical	-
39845056	2000	2003	DSS	Chemical	MESH:D016264
39845056	2012	2026	colonic injury	Disease	MESH:D003108
39845056	2103	2115	inflammation	Disease	MESH:D007249
39845056	2156	2163	LV149-H	Chemical	-
39845056	2203	2205	UC	Disease	MESH:D003093
39845056	2231	2243	inflammatory	Disease	MESH:D007249
39845056	Association	MESH:D007249	16193
39845056	Association	MESH:D007249	16176
39845056	Negative_Correlation	MESH:D007249	16153
39845056	Positive_Correlation	MESH:D016264	MESH:D003108
39845056	Positive_Correlation	MESH:D016264	MESH:D003093
39845056	Positive_Correlation	MESH:D016264	MESH:D003092

